[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100422773":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":82,"collaborators":84,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":11,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":11,"enrollmentInfo":96,"targetDuration":11,"studyType":99,"phases":100,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":43,"whyStopped":11,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Ascentage Pharma Group Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"APG-115+Toripalimab","EXPERIMENTAL",null,[13,14],"Drug: APG-115","Drug: Toripalimab",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":11},"DRUG","APG-115","Dose escalation of APG-115 in combination with label dose of toripalimab, four dose levels of APG-115 will be tested: 50, 100, 150, and 200mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3 weeks a cycle.",[9],{"type":17,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"Toripalimab","Toripalimab is administrated following CDE approved label dose, i.e.: 240 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.",[9],[26],{"name":27,"affiliation":28,"role":29},"Ye Guo, MD, PhD","Shanghai East Hospital","PRINCIPAL_INVESTIGATOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":11,"email":35},"Yifan Zhai, MD, PhD","CONTACT","+86-20-28068501","Yzhai@ascentage.com",{"name":37,"role":33,"phone":38,"phoneExt":11,"email":39},"Guojuan Chen, MD.","+86-20-28068520","guojuan.chen@ascentage.com",[41,57,72],{"facility":42,"status":43,"city":44,"state":45,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Sun Yat-sen University Cancer Center","RECRUITING","Guangzhou","Guangdong","China","CN",{"type":49,"coordinates":50},"Point",[51,52],113.25,23.11667,{"lat":52,"lon":51},[55],{"name":56,"role":33,"phone":11,"phoneExt":11,"email":11},"Xing Zhang, M.D.",{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":46,"countryCode":47,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Cancer Hospital of The University of Chinese Academy of Sciences","NOT_YET_RECRUITING","Hangzhou","Zhejiang","310005",{"type":49,"coordinates":64},[65,66],120.16142,30.29365,{"lat":66,"lon":65},[69,71],{"name":70,"role":33,"phone":11,"phoneExt":11,"email":11},"Meiyu Fang, Ph.D",{"name":70,"role":29,"phone":11,"phoneExt":11,"email":11},{"facility":73,"status":43,"city":74,"state":11,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Shanghai East Hospital (East Hospital affiliated to Tongji University)","Shanghai",{"type":49,"coordinates":76},[77,78],121.45806,31.22222,{"lat":78,"lon":77},[81],{"name":27,"role":33,"phone":11,"phoneExt":11,"email":11},{"type":83,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[85],{"name":86,"class":6},"Suzhou Yasheng Pharmaceutical Co., Ltd.","100422773","phase-1-apg-115-in-combination-with-pd-1-inhibitor-in-patients-with-advanced-liposarcoma-or-advanced-solid-tumors-100422773",false,"NCT04785196","APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","A Phase Ib\u002FII Study of APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Other Advanced Solid Tumors","Inclusion Criteria:\n\n1. Male or non-pregnant, non-lactating female patients age ≥18 years on day of signing the informed consent;\n2. ECOG PS 0-1;\n3. Phase Ib: Histologically confirmed, advanced liposarcoma or advanced solid tumor patients who failed standard of care therapy; Phase II: Histologically confirmed, advanced liposarcoma with TP53 wide-type and MDM2 Amplification;\n4. The expected survival period is more than 12 weeks;\n5. Measurable disease on CT or MRI by RECIST 1.1.\n6. Adequate bone marrow and organ function as indicated by: the following laboratory values without continuous supportive treatment (such as blood transfusion, coagulation factors and\u002For platelet infusion, red\u002Fwhite blood cell growth factor administration, or albumin infusion)\n\n   1. ANC≥1.5 x 10\\^9\u002F L;\n   2. PLT≥100 x 10\\^9\u002F L;\n   3. Hgb≥90 g\u002FL;\n   4. Alb≥30 g\u002FL;\n   5. AST and AST ≤3 \\* ULN (for hepatic metastases, ALT and AST≤5\\*ULN);\n   6. Serum creatinine (Cr) ≤ 1.5ULN or creatinine clearance (CCr) ≥ 50ml \u002F min.\n\nExclusion Criteria:\n\n1. Patients who have previously been treated with MDM2-p53 inhibitor;\n2. Known hypersensitivity reaction to PD-(L)1 inhibitors, or any prior ≥ Grade 3 irAE;\n3. Prior treatment consisted of any kinds of immunotherapies, like PD-(L)1 inhibitors, anti-PD-L2 antibodies, CTLA-4, OX-40 et.al( for phase II);\n4. Has known active central nervous (CNS) metastases and\u002For carcinomatous meningitis;\n5. Has any active or history of autoimmune disease;\n6. Active infection or unexplained fever \\> 38.5 ° C two weeks before first dose;\n7. Patients with any severe and\u002For uncontrolled diseases, including: hypertension and uncontrollable levels of normal anti-hypertensive medication; clinically significant cardiovascular and cerebrovascular diseases, including but not limited to severe acute myocardial infarction, unstable or severe angina, or coronary artery bypass surgery, congestive heart failure (New York Heart Association (NYHA) ) \\> 2);active or uncontrolled serious infection (≥CTCAE 5.0 Level 2 infection);objective evidence of previous or current history of pulmonary disease; moderate to severe hepatic impairment (Child-Pugh score ≥ 10 points); moderate to severe renal impairment or psychiatric illness\u002Fsocial circumstances that may affect study compliance;\n8. Poorly controlled arrhythmia (including QTc interval ≥450 ms for males and ≥470 ms for females).","ALL","18 Years",{"count":97,"type":98},95,"ESTIMATED","INTERVENTIONAL",[101,102],"PHASE1","PHASE2","Part 1 is a phase Ib standard \"3 + 3\" design, will be employed to determine the MTD of APG-115 by assessing the DLT of APG-115 in combination with PD-1 inhibitor(toripalimab) in advanced solid tumors.\n\nPart 2 is a Simon two-stage phase II study design. At RP2D of APG-115 in combination with toripalimab in advanced liposarcoma, approximately 34 patients will be treated with the combination until disease progression, unacceptable toxicity, or another discontinuation criterion is met.",[105,106],"Liposarcoma","Advanced Solid Tumor",[18,22,105,108],"Advanced solid tumors","2025-02-24",{"date":111,"type":112},"2025-02-26","ACTUAL",{"date":114,"type":112},"2021-05-26",{"date":116,"type":98},"2027-01",{"name":5,"class":6},3]